Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
July 27 2022 - 07:01AM
Business Wire
New ticker symbol (Nasdaq: QNCX) to initiate
trading on August 1, 2022
Cortexyme, Inc. (Nasdaq: CRTX) today announced that the
company’s planned corporate name change to Quince Therapeutics is
expected take effect on Monday, August 1, 2022. In conjunction with
the corporate name change, the company plans to issue a news
release that will provide a business update detailing Quince
Therapeutics’ go-forward growth strategy and development pipeline
plans.
Additionally, the company’s ticker symbol on the Nasdaq Global
Select Market is expected change to “QNCX” effective at the open of
market trading on Monday, August 1, 2022. The company’s common
stock will continue to trade under the ticker symbol “CRTX” until
market close on Friday, July 29, 2022. The corporate name change to
Quince Therapeutics does not affect the rights of the company’s
stockholders. Outstanding stock certificates are not affected by
the name change and will not need to be exchanged.
Quince Therapeutics also plans to launch its new corporate
website and social media presence on Twitter and LinkedIn on
Monday, August 1, 2022.
Forward-Looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast,” or other similar words. Examples
of forward-looking statements include, among others, statements we
make regarding our anticipated corporate name change and related
timing. Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict and could cause actual
results to differ materially from what the company expects.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in Cortexyme’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on
March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC
on May 10, 2022, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220727005263/en/
Cortexyme Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2023 to Mar 2024